Our Product – UbiHealth
Altratech has discovered and patented a fundamentally novel process to detect and quantify DNA, RNA, Antibody, and Antigen molecular targets. Our key breakthrough is that our process replaces the need for time consuming ‘biological amplification’ required for optical read-outs, with almost instant ‘electronic signal amplification’ and a digital read-out. This will enable market-disrupting products that have the simplicity of a pregnancy test and the performance of a laboratory PCR test.
In the emerging era of “test-and-treat” and “test-at-home” policies, UbiHealth will facilitate decentralisation of healthcare and enable many new benefits in point-of-care and in home telemedicine.
This is achieved in an all-synthetic robust assay which eliminates the need for centrifuges, pipettes, medically trained personnel, refrigeration or specialist equipment. Our novel ‘electronic signal amplification’ process can be applied to all molecular detection currently requiring ‘biological amplification’ e.g. PCR, LAMP & Sequencing, including high through put laboratory systems. Importantly, our product focus is on bringing to market a single use hand held device that we can prime with our proprietary PNA beads to target any virus or pathogen; and within the device we can multi-plex with multiple specific PNA beads, to detect up to twenty-four different viruses or pathogens in one single test.
Immediate encrypted digital wireless upload of results will enable realtime epidemiological tracking. In the emerging era of “test-and-treat” and “test-at-home” policies, UbiHealth will facilitate decentralisation of healthcare and enable many new benefits, at point-of-care and in home telemedicine.
